^
    Back
    Association details:
    Biomarker:PRC2 mutation
    Cancer:T Acute Lymphoblastic Leukemia
    Drug:JQ-1 (BET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EHA 2020
    Title:

    BETTING ON PRC2 ALTERATION IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA

    Published date:
    05/14/2020
    Excerpt:
    We treated T-ALL PDXs with the BET protein inhibitor JQ1 and showed that PRC2-altered PDXs are more sensitive than wild-type PDXs to BET inhibition.